drugset / Trial / NCT00005951

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

NCT00005951 ↗

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.

Timeline

Start
2000-08
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule — Intravenous
Subject Temozolomide Small molecule — Oral